Mutation Analysis of the Entire PKD1 Gene: Genetic and Diagnostic Implications  by Rossetti, Sandro et al.
Am. J. Hum. Genet. 68:46–63, 2001
46
Mutation Analysis of the Entire PKD1 Gene: Genetic and Diagnostic
Implications
Sandro Rossetti,1 Lana Strmecki,1 Vicki Gamble,2 Sarah Burton,3 Vicky Sneddon,1 Bele´n Peral,4
Sushmita Roy,5 Aysin Bakkaloglu,6 Radovan Komel,7 Christopher G. Winearls,3
and Peter C. Harris1
1Division of Nephrology, Mayo Clinic, Rochester, MN; 2Institute of Molecular Medicine, John Radcliffe Hospital, and 3Oxford Renal Unit, The
Oxford Radcliffe Hospital, Oxford, United Kingdom; 4Instituto de Investigaciones Biomedicas Alberto Sols, CSIC-UAM, Madrid; 5Institute of
Child Health, London; 6Department of Pediatric Nephrology, Hacettepe University, Ankara, Turkey; and 7Medical Centre for Molecular
Biology, Institute of Biochemistry, Ljubljana, Slovenia
Mutation screening of the major autosomal dominant polycystic kidney disease (ADPKD) locus, PKD1, has proved
difficult because of the large transcript and complex reiterated gene region. We have developed methods, employing
long polymerase chain reaction (PCR) and specific reverse transcription–PCR, to amplify all of the PKD1 coding
area. The gene was screened for mutations in 131 unrelated patients with ADPKD, using the protein-truncation
test and direct sequencing. Mutations were identified in 57 families, and, including 24 previously characterized
changes from this cohort, a detection rate of 52.3% was achieved in 155 families. Mutations were found in all
areas of the gene, from exons 1 to 46, with no clear hotspot identified. There was no significant difference in
mutation frequency between the single-copy and duplicated areas, but mutations were more than twice as frequent
in the 3′ half of the gene, compared with the 5′ half. The majority of changes were predicted to truncate the protein
through nonsense mutations (32%), insertions or deletions (29.6%), or splicing changes (6.2%), although the
figures were biased by the methods employed, and, in sequenced areas, ∼50% of all mutations were missense or
in-frame. Studies elsewhere have suggested that gene conversion may be a significant cause of mutation at PKD1,
but only 3 of 69 different mutations matched PKD1-like HG sequence. A relatively high rate of new PKD1mutation
was calculated, mutations per generation, consistent with the many different mutations identified (69551.8# 10
in 81 pedigrees) and suggesting significant selection against mutant alleles. The mutation detection rate, in this
study, of 150% is comparable to that achieved for other large multiexon genes and shows the feasibility of genetic
diagnosis in this disorder.
Introduction
Autosomal dominant polycystic kidney disease
(ADPKD) is the most common genetic nephropathology
(population frequency of ∼0.1%), which accounts for
5%–8% of end-stage renal disease (ESRD). The disease
is progressive, resulting in bilaterally enlarged polycystic
organs and typically causing ESRD in late middle age.
The disorder is genetically heterogeneous, with two
genes, PKD1 (∼85% of ADPKD pedigrees [MIM
60131]) and PKD2 (∼15% [MIM 173910]), identified
(European Polycystic Kidney Disease Consortium 1994;
Mochizuki et al. 1996), plus rare unlinked families de-
scribed elsewhere (Daoust et al. 1995). PKD1 encodes
a large multidomain protein, polycystin-1, with a variety
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of characterized domains and regions of homology with
other proteins (Hughes et al. 1995; International Poly-
cystic Kidney Disease Consortium 1995; Moy et al.
1996; Sandford et al. 1997). Polycystin-1 may play a
role in cell:cell/matrix interactions (Huan and van Adels-
berg 1999; Wilson et al. 1999), whereas polycystin-2
(the PKD2 protein) has homology to an ion-channel sub-
unit (Mochizuki et al. 1996; Chen et al. 1999).
PKD1 accounts for most cases of ADPKD associated
with ESRD, because it is more common and results in
significantly more-severe disease (average age at onset
of ESRD is 53 years, compared with 69.1 years for
PKD2; Hateboer et al. 1999). However, genetic diag-
nosis at this locus has proceeded slowly, because (1)
PKD1 contains a 12,906-bp coding sequence (Hughes
et al. 1995) divided into 46 exons, and (2) the 5′ region
of the gene, from upstream of exon 1 to exon 33, is
embedded in a complex genomic area reiterated 14
times further, proximally, on the same chromosome (Eu-
ropean Polycystic Kidney Disease Consortium 1994).
Analysis of two copies of these PKD1-like homologous
genes (HG) has shown a number of specific deletions
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Table 1
Primers for Specific Amplification of PKD1
Fragment Primer Sequencea
Annealing
Temperature
(C) Position
Size
(bp) Exon(s)
cDNA:
Spec 1 (F) CTACGTCTGCGAGCTGCAGCCC 66 1792–4000 2,209 7–15
(R) CACATGCTCCACTGTTGCCTCC
Spec 2 (F) CCGTCACCTTCTACCCGCACCC 68 3639–5519 1,881 15
(R) TATGGGTGGTAAATGGCTCGGA
Spec 3 (F) TGGTTAGGGATGGCACCAACG 65 5175–7121 1,947 15
(R) TCGAAGCCACACAGGCCCAG
Spec 4 (F) GGCGATCACAGCGCAACTACT 66 6696–8901 2,206 15–23
(R) ACGGAGTTGGCGGAGTTGGC
Genomic:
Gen 1b (F) CGCAGCCTTACCATCCACCT 64 2033–4310 2,278 1
(R) TCATCGCCCCTTCCTAAGCA
Gen 2–10b (F) CCAGCTCTCTGTCTACTCACCTCCGCATCGCCTGCA 68 17647–24008 6,362 2–10
(R) GGCTGGGTGTGTCTGGTGCA
Gen 22–33b (F) GAGCCAGGTGAGGACCCGTGTA 68 36868–44310 7,442 22–33
(R) TGAGCTTCAGAGCCCCCTCCTC
a Underlined nucleotides differ between PKD1 and all characterized HG sequence.
b One primer absent in all known HG sequence.
and a low level of substitutions (∼2%), compared with
PKD1 (Loftus et al. 1999). The presence of the HG loci
has significantly complicated analysis of PKD1, with
routine PCR amplification and hybridization detecting
those loci as well as PKD1. Consequently, the number
of identified PKD1 mutations is still limited, with 82
changes described in the Online Human Gene Mutation
Database (HGMD) (Krawczak and Cooper 1997). Al-
though a number of methods have been employed to
screen the reiterated region (Peral et al. 1997; Roelfsema
et al. 1997; Watnick et al. 1997, 1998a, 1999; Thomas
et al. 1999), the 3′ area has received disproportionate
attention, with 57.3% of all mutations found in the
single-copy area covering ∼20% of the coding region.
It has not been possible to assess whether some areas
are more prone to mutation, since no systematic study
of the entire gene has been described. Analysis of the
less-complex PKD2 has yielded 41 mutations (see
HGMD), which are found throughout the gene and are
mainly predicted to truncate and probably inactivate
the protein (Veldhuisen et al. 1997). The majority of
PKD1 mutations are also predicted to truncate the pro-
tein, although a significant number of missense changes
have been described elsewhere (Peral et al. 1997; Dan-
iells et al. 1998; Perrichot et al. 1999; Thomas et al.
1999).
Inactivating germline mutations are consistent with
the hypothesis that cystogenesis occurs by a two-hit
mechanism in which a cyst only forms after the normal
ADPKD allele has been inactivated by a somatic mu-
tation. Evidence for this mechanism comes from the
finding of somatic mutations in the PKD1 gene in cystic
epithelia isolated from single cysts in PKD1 renal and
liver tissue (Qian et al. 1996; Watnick et al. 1998b) and
corresponding results in material from patients with
PKD2 (Koptides et al. 1999; Pei et al. 1999; Torra et
al. 1999). Recently, it has been suggested that cysts may
evolve by a transheterozygous method, with a germline
mutation to PKD2 and a somatic mutation to PKD1
or vice versa (Koptides et al. 2000; Watnick et al. 2000).
Further evidence that germline mutations may be in-
activating comes from knockout models of Pkd1 and
Pkd2; homozygotes generally die in the mid- to late-
fetal stages, with renal and pancreatic cysts developing
from ∼E14.5d, whereas heterozygotes develop occa-
sional cysts in later life (Lu et al. 1997, 1999; Kim et
al. 2000). Nevertheless, there are questions of whether
mutant polycystin-1 molecules, at least in some cases,
may have residual function or even an altered role. Tar-
geted disruption of Pkd1 in the 3′ region has a more
severe phenotype than disruption of the gene in exon
34, suggesting a dominant negative role for the larger
mutant protein (Lu et al. 1997; Kim et al. 2000). Studies
of human cystic epithelia have also found strong po-
lycystin-1 staining in many cyst linings, suggesting the
presence of normal or mutant polycystin-1 protein and
not entirely consistent with the predicted two-hit model
(Geng et al. 1996; Ward et al. 1996; Ong et al. 1999).
The necessity for numerous somatic mutations to ex-
plain the formation of multiple cysts and evidence of a
significant rate of new germline mutations (Peral et al.
1997) have led to the proposal that unusual mechanisms
promote a high rate of PKD1 mutation. First, a long
polypyrimidine tract in IVS21, which could potentially
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Table 2
PTT and Sequencing Primers
Fragment Sequence
Annealing
Temperature
(C)
Position
(cDNA)
Size
(bp) Exon(s)
cDNA:
PTT 1 (F) GATGCCGAGAACCTCCTCG 63 1829–3869 2,041 8–15
(R) TCATGTCCACGCTGAGTCCG
PTT 2 (F) GCCAACCACACCTATGCCTCG 62 3740–5431 1,692 15
(R) GGCACTGAGGGTGACGCTTGT
PTT 3 (F) AGCGGCAAAGGCTTCTCGCTC 66 5246–7052 1,807 15
(R) ACTCGCTCCCATCCAGCACC
PTT 4 (F) ACTGAGTACCGCTGGGAGGTGTATC 66 6758–7942 1,185 15–20
(R) GGGCTCTGGGAGGGTGATG
PTT 5 (F) AAGACGCTGGTGCTGGATGAG 62 7448–8644 1,197 18–23
(R) AGCCTCGGGGATGGAGAAG
cSeq 1 (F) TGAGTACCGCTGGGAGGTGTATC 62 6760–7336 577 15–17
(R) TGCCTTGCAGGACACACACTC
cSeq 2 (F) TGTCCCTGAGGGTCCACACTG 62 8163–8681 519 22–23
(R) GCACCACGTCACTGAGGTTGG
cSeq 3 (F) CTCAACGAGGAGCCCCTGAC 62 8516–9126 611 23–24
(R) TCAGCACCCTGGAGTGACTCTG
cSeq 4 (F) CAGTCTACCTACACTCGGAGCCC 62 9039–9648 610 24–27
(R) TCCACCCCATACAGCATGATG
Genomic:
GenSeq 1 (F) CCTGAGCTGCGGCCTCCG 64 3580–3799 220 1
(R) CAGTTGACGCGGCAGGCG
GenSeq 2 (F) TGCGAGCCCCCCTGCCTC 66 3744–3923 180 1
(R) AACCCGCCCACGCCCGCCCGTCC
GenSeq 3 (F) CTTGGGGATGCTGGCAATG 59 19810–20239 430 2–3
(R) AACTGGGAGGGCAGAAGGG
GenSeq 4 (F) AGTGGGGGGCTGGCATAGAC 64 20371–21017 647 4–5
(R) GCAAAGGAGGCACTGGAGGG
GenSeq 5 (F) CTTCTAGGTGAGGAGTATGTCGCC 64 20812–21593 782 5
(R) AACGAGGGTGTCAACGGTCAG
GenSeq 6 (F) ACCGTTGACACCCTCGTTCC 60 21576–21855 280 6
(R) TCTCTGCCCCAGTGCTTCAG
GenSeq 7 (F) CTGTGAGGGTGGGAGGATGG 64 22166–22787 622 7–8
(R) GGAGGGCAGGTTGTAGAACGTG
form triplex DNA structures (Van Raay et al. 1996;
Blaszak et al. 1999), has been implicated in inducing
mutations in the downstream exons (Watnick et al.
1997). Subsequently, these multiple substitutions, and
other changes, were found to match HG sequence, sug-
gesting gene conversion with the distantly located HG
loci (Watnick et al. 1998a; Phakdeekitcharoen et al.
2000). At this stage, the importance of these unusual
mechanisms for causing mutation at PKD1 are unclear,
as is the question of whether mutation is occurring at
a higher than average level.
In this study, we describe techniques for mutation
analysis of the entire PKD1 gene. We have employed
these methods to screen a cohort of 155 apparently
unrelated ADPKD pedigrees, to generate a clearer view
of the pattern of mutation at PKD1 and the prospects
for molecular diagnostics.
Subjects and Methods
Patients with ADPKD
Patients were recruited through the Oxford Renal Unit
(135 pedigrees), other adult nephrology centers (7 ped-
igrees), or pediatric nephrology units (13 pedigrees). In
each case, the proband had ADPKD, as defined by the
Ravine criteria for ultrasound examination (Ravine et
al. 1994). Most cases had typical ADPKD, but the group
also included 10 pedigrees that comprised a case of early-
onset ADPKD. Informed consent was obtained and
blood samples collected for DNA isolation from the pro-
band and from all available family members. At-risk
undiagnosed individuals wishing to take part in the
study were examined by abdominal ultrasound. The
study had approval from the University of Oxford Ethics
Committee.
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Genetic Linkage Analysis
Pedigrees with more than six informative meioses were
analyzed for linkage to PKD1 or PKD2 with microsat-
ellite markers. The markers KG8, SM6, 16AC2.5, and
CW2 were routinely employed for PKD1 linkage (Peral
et al. 1994) and haplotype analysis of recurrent muta-
tions. The markers D4S1534, D4S1563, D4S423, and
JSTG3 were employed for analysis of PKD2 (Gyapay et
al. 1994; Mochizuki et al. 1996). The markers were
amplified and analyzed on native polyacrylamide gels,
as described elsewhere (Harris et al. 1991; Peral et al.
1994).
Amplification of the PKD1 transcript
RNA isolation from lymphoblast cell lines and leu-
kocytes and reverse transcription (RT)–PCR for cDNA
synthesis were performed as described elsewhere (Eu-
ropean Polycystic Kidney Disease Consortium 1994;
Peral et al. 1997). Primer pairs for specific amplification
of PKD1 cDNA (exons 7–23; see fig. 1) are shown in
table 1 (top). These were designed to match regions
where the PKD1 and HG sequence differ, with the mis-
matches positioned at the 3′ ends of the primers to max-
imize specificity. Patient cDNA was amplified at high
annealing temperatures (see table 1, top) in a DMSO-
containing buffer (Dode´ et al. 1990) with a 90-s exten-
sion time and the addition of Taq Extender (1 U/kb
amplified; Stratagene). The specificity of fragments was
tested with HG-only somatic cell hybrids, P-MWH2A
and 77-2/1 (containing the der16 chromosome of patient
77-2; European Polycystic Kidney Disease Consortium
1994), and the PKD1-only radiation hybrid, Hy145.19
(European Polycystic Kidney Disease Consortium 1994).
Details of the primer pairs to amplify exons 22–46 (Spec
5–7) have been described elsewhere (Peral et al. 1997).
Amplification of the PKD1 gene
Genomic DNA was isolated from peripheral blood by
standard phenol/chloroform extraction methods. The
primer pairs used to amplify PKD1 genomic fragments
are shown in table 1 (bottom), as is their PKD1 speci-
ficity, tested employing the somatic cell hybrid panel.
Long PCR to amplify Gen 2–10 and Gen 22–33 was
performed using the Gene Amp XL Kit (PE Biosytems)
and a hot-start protocol. In brief, each reaction con-
taining 60 ng genomic DNA, 5 pmol each primer, 200
mM each dNTP, 1 mM Mg(OAc), and the supplied buffer
was heated to 93C for 3 min. Subsequently, 1 U rTth
enzyme was added, and the reaction was incubated for
35 cycles of 93C, 60 s; 68C, 60 s; and 70C, 6 min.
Because of the extreme GC richness of exon 1, a dif-
ferent protocol was employed: DNA (120 ng), primers
(8 pmol each), dNTPs (200 mM each), and MgCl2 (2.5
mM) was heated to 100C for 5 min. On cooling to
95C, the DMSO buffer, Taq Extender (4 U), and Am-
plitaq (2 U) were added before 15 cycles of 95C for 60
s, 64C for 60 s, and 72C for 3 min. Subsequently, 20
further cycles were completed using the conditions as
described above, with the addition of 10 s to each an-
nealing step and of 20 s per extension step and, finally,
72C for 10 min.
Protein Truncation Test (PTT)
A ∼1:1000 dilution of the appropriate Spec PCR prod-
uct was amplified using the PTT primer sets (see table
2, top, and Peral et al. [1997] for details of fragments
PTT 6–9). Each upstream PTT primer had additional 5′
sequence added containing the T7 promoter and trans-
lation-initiation codon (Roest et al. 1993). Details of the
transcription, translation, and analysis of the resulting
polypeptide products have been described elsewhere
(Peral et al. 1997). Smaller constant bands were some-
times seen (see fig. 2) because of translational initiation
from internal start codons (Rowan and Bodmer 1997).
DNA Sequencing
Sequencing of cDNA was used to analyze four frag-
ments (cSeq 1–4) (fig. 1) and to characterize mutations
detected by PTT and other methods. Genomic sequenc-
ing was used to screen the 5′ region of the gene (exons
1–8) and to confirm other mutations. The method of
dye primer sequencing was employed with primers (see
table 2) modified by addition to the 5′ end with the21
M13 universal primer sequence: 5′-TGTAAAACGACG-
GCCAGT-3′ (upstream) and the 28 M13 reverse
primer sequence: 5′-AGGAAACAGCTATGACCAA-3′
(downstream). Appropriate PKD1-specific DNA was di-
luted ∼1:1000 and was amplified with the modified se-
quencing primer using the protocol 94C for 1 min; 30
cycles of 94C for 30 s, 59C–66C (see table 2) for 30
s, and 72C for 30 s; and, finally, 72C for 10 min.
Amplification of exon 1 was as described above, except
that a denaturation step of 100C for 5 min was added
before addition of the enzyme, and annealing and elon-
gation times were extended as for the primary amplifi-
cation of exon 1. Products from these PCR reactions
(200 ng) were used for sequencing employing the BigDye
Primer Cycle Sequencing Reaction Kit with the appro-
priate M13 primer (PE Biosystems). The cycle sequenc-
ing consisted of 15 cycles of 95C for 30 s, 55C for 30
s, and 70C for 60 s and 15 cycles of 95C for 30 s and
70C for 60 s. The four different primer reactions were
mixed and precipitated with ethanol, and the pellet was
resuspended in loading buffer (95% formamide, 0.01%
bromophenol blue). The reactions were run on an ABI
Figure 1 Diagram showing the fragments employed for mutation screening of the PKD1 gene and the mutations detected. The PKD1 gene (top) and transcript (bottom), showing the intron/
exon structure, duplicated region (blue), single-copy coding exons (solid boxes), and 5′ and 3′ UTRs (open boxes). The positions of fragments to amplify the transcript specifically (Spec; blue), plus
the PTT fragments (PTT; red) and cDNA sequencing products (cSeq; green), are shown at the bottom. The locations of the PKD1-specific and anchored genomic fragments (Gen; blue), plus the
genomic sequencing products (GenSeq; green), are illustrated at the top. The sites of the mutations detected in the 81 different PKD1 pedigrees (P) are shown in the center. Different mutation types
are color coded and grouped: splicing mutations, turquoise; frameshifting deletions or insertions, purple; in-frame deletions or insertions, green; nonsense mutations, red; and missense mutations,
dark blue. Newly described mutations are shown in boldface type.
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Figure 2 Examples of PTT gels. A, Fragment PTT3, transcripted and translated from cDNA of mouse; human (Normal); somatic-cell
hybrids, 77-2/1 and P-MWH2A (HG only; lane 2 and 6, respectively); P-SHH1H; whole chromosome 16 (16 hybrid); and the radiation hybrid,
Hy145.19 (PKD1 only). The product is only generated in PKD1-containing samples showing the specificity of this PTT assay. Analysis of PKD1
patient and normal cDNA by PTT assays, PTT1 (B) and PTT4 (C). The pedigree number and detected mutation are shown for each sample.
Mutant polypeptides are seen as smaller products on the gel.
PRISM 377 sequencer, and the resulting sequence was
analyzed with SEQUENCER 3.0 software.
Heteroduplex Analysis
The PCR product to be assayed was denatured at 95C
for 5 min and then was incubated at 37C for 2 h. These
products were separated on a 10% PAGE at 200 V for
20 h and were visualized after staining with ethidium
bromide.
Allele-Specific Oligonucleotides (ASOs)
To confirm the mutations, 7205del7 and 6937delAC,
oligonucleotides were designed matching either the nor-
mal or mutant sequence, with the mismatch in the mid-
dle of the primer. The oligonucleotides were end labeled
with 32P; hybridized to a dot blot containing the am-
plified target sequence from the patient, family members,
and normal controls; washed; and exposed to x-ray film
(Wood et al. 1985). Differential hybridization of the oli-
gonucleotides was used to confirm the mutation and
trace the change within families.
Signal Peptide Prediction
The SPSCAN program in the SeqWeb package (GCG)
was used to predict the probability of signal peptides,
using the eukaryotic scoring matrix (Nielsen et al. 1997).
Hydrophobicity measurements were made with Mac-
Vector, using the Kyle-Doolittle plot with a window size
of 20 residues.
Sequence Designation
The positions of primers and mutations are shown
relative to the PKD1 genomic (GenBank accession
number L39891), cDNA (GenBank accession number
L33243), and protein sequence (GenBank accession
number AAC37576).
Results
Strategy for Mutation Screening
To overcome the problem of duplication of the 5′ re-
gion of PKD1, we employed different strategies to spe-
cifically amplify the gene. For the region from exons 9
to 46, PKD1-specific fragments were amplified from
cDNA generated from lymphoblast or leukocyte RNA
(fig. 1). The duplicated area from exons 23–32 and the
single-copy 3′ region was amplified as described else-
where (Peral et al. 1997), with one or both primers in
the single-copy area to provide PKD1 specificity. For
exons 9–23, a method of PKD1-specific amplification
was employed, using primers that match the rare dif-
ferences between PKD1 and HG sequence.HG sequence
Table 3
Details of Newly Identified PKD1 Mutations
Pedigree
Mutation
Designation
Method of
Detectiona Confirmationb
Segregation
Demonstrated
Pedigree
Sizec
PKD1
Linkedd
Family
Historye
Normal
Chromosomes
P1 IVS71GrA Gen seq Gen digest: MnlI Yes 54 Yes Yes
P2 7205del7 PTT Gen ASO Yes 3 Yes De novo
P7 C2370X PTT Leuk PTT NP 4 NP Yes
P8 7324delGT PTT Leuk PTT Yes 5 Yes De novo
P9 6645del28 PTT Gen hetero Yes 6 NP Yes
P13 C2229X PTT/cDNA seq Gen Seq Yes 23 Yes Yes
P14 6868del15 cDNA seq Gen Gel Yes 10 Yes Yes
P17 Q2243X PTT Rel-cDNA seq Yes 29 Yes Yes
P17A Q2243X PTT Rel-cDNA seq Yes 15 Yes Yes
P18 E1537X PTT Rel-PTT Yes 12 Yes Yes
P99 2296delC PTT Gen seq NP 2 NP ?
P103 224delC Gen seq Gen hetero Yes 8 Yes Yes
P105 Q3513X Gen digest, AlwNI Gen seq Yes 4 NP Yes
P107 6937 delAC PTT Gen hetero/ASO NP 1 NP No
P118 8126dup20 PTT Rel-PTT/hetero Yes 2 NP De novo/EO
P124 9245del18 Gen gel Gen seq Yes 5 NP Yes
P126 R2163X PTT Gen digest, BclI Yes 2 NP ?
P134 IVS91GrT PTT Rel-PTT Yes 4 NP Yes
P135 A2752D cDNA seq Gen digest, StuI Yes 4 NP Yes 0/250
P148 E2771K cDNA seq Gen digest, BseRI Yes 6 Yes Yes/EO 0/230
P152 IVS212delAG cDNA seq Gen seq Yes 2 NP De novo
P159 S75F Gen seq Rel-Gen seq Yes 2 NP Yes/EO 0/98
P164 6356insG PTT Leuk PTT NP 3 NP Yes
P169 7211dup7 PTT Rel-PTT Yes 6 NP Yes/EO
P178 IVS2516GrA PTT Leuk PTT/gen digest, PvuII NP 1 NP ?
P184 4291delG PTT Gen seq NP 2 NP ?
P190 8507ins12 cDNA seq Gen gel Yes 2 NP No/EO
P200 7211dup 7 PTT Leuk PTT NP 6 NP Yes
P204 F1992L  1993delT cDNA seq Gen digest, DdeI NP 1 NP No 0/106
P216 7205del7 PTT Gen ASO Yes 3 NP No
P220 Y2336D cDNA seq Gen digest, RsaI Yes 3 NP No 0/180
P224 6937delAC PTT Gen hetero Yes 7 Yes Yes
P227 R2430X PTT Leuk cDNA digest, SphI NP 2 NP ?
P228 L2816P cDNA seq Gen digest, MscI Yes 5 Yes Yes 0/350
P234 4137delCT PTT Gen hetero Yes 3 NP ?
P236 5870del14 PTT Gen hetero Yes 3 NP Yes
P252 R4227X ARMS Gen seq Yes 7 Yes Yes
P255 Q705X PTT Gen seq Yes 4 Yes Yes
P256 E2771K cDNA seq Gen digest, BseRI Yes 7 NP Yes 0/230
P264 R4020X Gen digest, Ddel Gen seq Yes 5 NP Yes
P267 W139C Gen seq Rel-gen seq Yes 7 NP Yes
P285 L13Q Gen seq Gen seq NP 2 NP Yes 0/98
P292 Q3394X PTT Gen seq NP 3 NP Yes
P314 4784delG PTT Gen seq NP 1 NP ?
P322 W3180X PTT Leuk PTT NP 4 NP ?
P344 R2430X PTT Leuk cDNA digest, SphI NP 1 NP ?
P398 S749X PTT Gen seq NP 2 NP ?
P399 2296insC PTT Gen seq NP 5 Yes Yes
P402 IVS22AG Gen seq Gen digest, MspI NP 4 NP Yes
P404 C2229X PTT/cDNA seq Gen seq NP 2 NP Yes
P407 Y4039X PTT Gen digest, DdeI NP 1 NP No
P408 Q227X Gen seq Gen seq NP 4 NP Yes
P442 V2768M  G2858S cDNA seq Gen digest, SphI and BsaHI Yes 2 NP No 0/250
P447 E2771K cDNA seq Gen seq, BseRI NP 3 Yes Yes 0/230
P491 12617delC PTT Gen digest, BspMI NP 2 NP ?
P499 S225X Gen seq Rel-gen seq Yes 2 NP No
P511 E2771K cDNA seq Gen seq, BseRI NP 1 NP ? 0/230
a Gen seq p genomic sequencing; PTT p protein truncation test; cDNA seqp cDNA sequencing; Gen digestp genomic digestion; and ARMSp amplification
refractory mutation system.
b Gen ASO p genomic-allele specific oligonucleotide hybridization; Leuk PTT p PTT using leukocyte-isolated RNA; Gen gel p genomic gel electrophoresis;
Rel p change confirmed in affected relative; Hetero p heteroduplex analysis.
c No. of traced affected cases.
d Prior to mutation detection; NP p not possible to test because of insufficient family members/samples.
e EO p early onset.
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was obtained from HG cDNAs (European Polycystic
Kidney Disease Consortium 1994) and from genomic
sequence of HG loci (Loftus et al. 1999; authors’ un-
published data). The rare sequence differences were po-
sitioned at the 3′ ends of primers, to maximize their
specifying effect (see table 1). The PKD1 specificity of
each fragment was tested using somatic cell hybrids con-
taining just the PKD1 or HG loci (see, e.g., fig. 2A). For
the region from exons 1–8, PKD1-specific amplification
of cDNA proved impossible, because of the lack of dif-
ferences between the PKD1 and HG transcripts. Con-
sequently, this region was amplified by long PCR em-
ploying a genomic DNA template. Specificity for the
exon 2–8 region was obtained by positioning the 5′
primer in a region of IVS 1 deleted in the HG1 and HG2
loci (Loftus et al. 1999) and with a specific 3′ primer
(Gen 2–10; table 1, bottom, and fig. 1). A novel HG
locus has recently been sequenced (HG3) that contains
the IVS 1 primer but is deleted for the 3′ primer and so
is also not amplified with this primer pair (data not
shown). The GC-rich exon 1 was amplified from ge-
nomic DNA using one primer 5′ to the duplicated region,
to provide PKD1 specificity, and a second primer in IVS
1 (Gen 1 fig. 1 and table 1, bottom). A long PCR linking
the single copy area to IVS 21 (Gen 22–33; table 1,
bottom, and fig. 1) was also developed to test the validity
of mutations found in exons 22–32.
Exons 9–46 were screened for mutations using the
PTT, with nine overlapping fragments (for details, see
table 2 and fig. 1). Exons 1–9 were screened by direct
sequencing of PKD1 exons using seven sets of modified
primers (GenSeq 1–7; table 2, top, and fig. 1). The areas
from exons 21–26 and the 3′ ends of exons 15 and 16
also were analyzed by direct sequencing of cDNA.
Each identified mutation was confirmed using an in-
dependent method (for details, see table 3). WherePKD1
genomic DNA was readily specifically amplified, the
confirmation was by genome sequencing, restriction di-
gest, or other method. In other cases, PTT, sequencing,
or restriction digest employed cDNA from a relative or
leukocyte cDNA from the proband. When samples were
available, segregation within the family was tested (see
table 3). This was especially important for potential mis-
sense mutations and subtle in-frame changes that were
also screened in98 normal chromosomes (see table 3).
Only if the change segregated with the disease (except
P285; see below) and was not seen in the normal pop-
ulation was it considered a possible missense mutation.
All probands with putative missense changes were in-
cluded in the screen of subsequent fragments, but no
further changes were found in these samples in the rest
of the gene.
Population Screened for PKD1 Mutations
A total of 131 patients from apparently unrelated fam-
ilies were screened for PKD1 mutations in this study.
These included 73 patients that were negative in previous
rounds of mutation detection from exons 23–46 (Eu-
ropean Polycystic Kidney Disease Consortium 1994;
Peral et al. 1995, 1996a, 1996b, 1997; Torra et al.
1998), in which a total of 24 mutations were charac-
terized. Of the ADPKD pedigrees in the present study,
34 were linked to PKD1, and the remainder were from
families that were too small (or too few samples were
available) for linkage analysis. Six families found to be
linked to PKD2, or to have PKD2 mutations (authors’
unpublished data), were eliminated from the study pop-
ulation. Analysis for larger rearrangements by hybridi-
zation of field inversion gels of EcoRI-digested DNA
identified no further rearrangements than the two de-
scribed elsewhere (European Polycystic Kidney Disease
Consortium 1994).
Mutations Detected by PTT
PTT was employed as a screening method for most
of the gene, because relatively large fragments could be
assayed and practically all detected changes were path-
ogenic mutations, overcoming the problem of significant
polymorphism in PKD1. In the nine PTT fragments
(covering 87.5% of the coding area), 27 different mu-
tations were found in 33 families (for details, see table
4 and fig. 1). PTT gels showing PKD1 specificity of
amplification and examples of mutations are shown in
figure 2. The mutation in each case was identified by
direct sequencing of cDNA, with splicing changes char-
acterized in genomic DNA. An example of segregation
of the splicing change IVS71GrA, which was detected
in a large family (P1) that was originally used to map
PKD1 to 16p13.3 (Reeders et al. 1985; NDM-A), is
illustrated in figure 4A. The PTT changes consisted of
10 frame-shifting deletions, 4 insertions, 11 nonsense
mutations, and 2 frame-shifting splicing changes. In
P178, exon 26 was skipped, but the only detected ge-
nomic change was IVS2516GrA. It is not clear how
this causes exon skipping, but the introduction of an A
nucleotide may disrupt branch-site formation. The mu-
tation associated with one aberrant PTT fragment de-
tected in two pedigrees was not identified initially by
sequencing but was rediscovered as the nonsense mu-
tation C2229X during direct sequencing of the area.
Mutations Detected by Direct Sequencing
The region from exons 1–8 was analyzed by direct
sequencing in genomic DNA, and eight different mu-
tations were detected: two stop codons, two splicing
changes, one deletion, and three missense changes (for
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Table 4
Summary of PKD1 Mutation Changes Identified in the Study Population
Designation Location
cDNA
Change(s)
Amino
Acid
Changea Comments Pedigree(s) Reference(s)
Nonsense:
S225X EX5 885CrA 225f At CpG P499 Present study
Q227X EX5 890CrT 227f P408 Present study
Q705X EX11 2324CrT 705f P255 Present study
S749X EX11 2457CrG 749f P398 Present study
E1537X EX15 4820GrT 1537f At CpG P18 Present study
R2163X EX15 6698CrT 2163f CrT at CpG P126 Present study
C2229X EX15 6898CrA 2229f P13, P404 Present study
Q2243X EX15 6938CrT 2243f P17, P17A Present study
C2370X EX17 7321TrA 2370f P7 Present study
R2430X EX18 7499CrT 2430f CrT at CpG, matches HG 1, 2, and 3 P227, P344 Present study
E3020X EX25 9269GrT 3020f At CpG P130 Peral et al. (1997)
W3180X EX27 9751GrA 3180f P322 Present study
Q3394X EX32 10391CrT 3394f P292 Present study
Q3513X EX35 10748CrT 3513f P105, P187 Peral et al. (1997); present study
Y3818X EX41 11665CrA 3818f At CpG P117 Peral et al. (1996a)
Q3837X EX41 11720CrT 3837f P198 Peral et al. (1996b)
R4020X EX44 12269CrT 4020f CrT at CpG P264 Present study
Y4039X EX44 12328CrA 4039f At CpG P407 Present study
Q4041X EX44 12332CrT 4041f P284 Torra et al. (1998)
R4227X EX46 12890CrT 4227f CrT at CpG P3, P89,
P252
Peral et al. 1996b, 1997); present study
Deletion or insertion:
Frameshift:
224del13 EX1 224del13 4f 8-bp repeat 13 bp apart P103 Present study
2296delC EX10 2296delC 695f 6 # C nt P99 Present study
2296insC EX10 2296insC 695f 6 # C nt P399 Present study
4137delCT EX15 4137delCT 1308f P234 Present study
4291delG EX15 4291delG 1360f P184 Present study
4784delG EX15 4784delG 1524f P314 Present study
5870del14 EX15 5870del14 1886f 7-bp repetition, 14 bp apart P236 Present study
6937delAC EX15 6937delAC 2242f 2 # AC repeats P107, P224 Present study
7205del7 EX15 7205del7 2331f 7-bp direct repeat P2, P216 Present study
7211ins7 EX16 7211ins7 2333f 7-bp direct repeat P169, P200 Present study
7324delGT EX17 7324delGT 2371f 4 # GT repeats P8 Present study
8126ins20 EX21 8126ins20 2638f 9#bp repeat, 20 bp apart P118 Present study
8657delC EX23 8657delC 2815f 3 # C nt P179 Peral et al. (1997)
9299delC EX25 9299delC 3029f P11 Peral et al. (1997)
IVS30del2 kb IVS30IVS34 10262del446 3350f P98 European Polycystic Kidney Disease
Consortium (1994)
IVS34del5.5 kb IVS343′UTR 10708del to 3′UTR 3499f P95 European Polycystic Kidney Disease
Consortium (1994)
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10947insT EX36 10947insT 3578f P100 Peral et al. (1996a)
12617delC EX45 12617delC 4135f P491 Present study
12739delA EX46 12739delA 4176f Flanked by 5 # C/3 # C P225 Peral et al. (1997)
In frame:
F1992L, 1993delT EX15 6187delC 1992*D1993 P204 Present study
6868del15 EX15 6868del15 D2220–2224 13-bp repeat, 15 bp apart P14 Present study
8507ins12 EX23 8507dup12 2762–2765 10-bp repeat, 12 bp apart P190 Present study
9245del18 EX25 9245del18 D3012–3017 Incomplete repeat (13/18), 18 bp apart P124 Present study
11457del15 EX39 11457del15 D3749–3753 7-bp repeat, 15 bp apart P35 Peral et al. (1996b)
Splicing:
Frameshift:
IVS71GrA IVS7 1597del221 536f Skip exon 7 P1 Present study
IVS91GrT IVS9 1934del127 574f Skip exon 9 P134 Present study
IVS2516GrA IVS25 9413del196 3067f Skip exon 26, CrT at CpG P178 Present study
IVS3125del9 IVS31 10378ins71 3389f Inclusion IVS 31, matches HG1, 12-bp
repeat, 19 bp apart
P229 Peral et al. (1997)
IVS391GrC IVS39 11365del113 3717f Skip exon 39 P109 Peral et al. (1997)
In frame:
IVS22ArG IVS2 499del72 D97–120 Skip exon 3 P402 Present study
IVS212delAG IVS21 8228del42 D2673–2686 Cryptic splice exon 22 P152 Present study
IVS3925del72 IVS39 11478del51 D3756–3772 5-bp repeat 67 bp apart; cryptic splice
exon 40
P167 Peral et al. (1996b)
IVS4317del18 IVS43 11921del291  others D3904–4000  others 9-bp repeat 20 bp apart S6046 Peral et al. (1995)
IVS4314del20 IVS43 11921del291  others D3904–4000  others 9-bp repeat 20 bp apart P138 Peral et al. (1995)
IVS441GrC IVS44 12212del135 D4001–4045 Skip exon 44 P4 European Polycystic Kidney Disease
Consortium (1994)
Missense:
Nonconservative:
L13Q EX1 249TrA L13Q P285 Present study
S75F EX2 435CrT S75F P159 Present study
W139C EX4 628GrT W139C P267 Present study
Y2336D EX16 7217TrG Y2336D P220 Present study
A2752D EX23 8466CrA A2752D P135 Present study
V2768M EX23 8513GrA V2768M CrT at CpG P442 Present study
G2858S EX23 8783GrA G2858S CrT at CpG P442 Present study
E2771K EX23 8522GrA E2771K CrT at CpG P148, P256,
P447, P511
Present study
L2816P EX23 8658TrC L2816P Matches HG1, 2, and 3 P228 Present study
L2993P EX25 9189TrC L2993P P193 Peral et al. (1997)
Q3016R EX25 9258ArG Q3016R P157 Peral et al. (1997)
Conservative:
L3510V EX35 10739CrG L3510V P161 Peral et al. (1997)
E3631D EX37 11104GrC E3631D P125 Peral et al. (1996b)
a f p Frameshift after indicated residue; D p deletion of indicated residues (inclusive);  p duplication of indicated residues (inclusive).
56 Am. J. Hum. Genet. 68:46–63, 2001
Table 5
Polymorphisms Identified in the Study Population
Designation Location
cDNA Change
or Amino Acid
Position Comments Enzyme Frequency (%) Reference
Amino acid change:
P/S2674 EX22 8231C/T AvaII 7/348 (2.0) Present study
T/M2708 EX22 8334C/T BsaHI 5/318 (1.8) Present study
P/T2734 EX23 8411C/A BanI 1/340 (.3) Present study
Q/L 2735 EX23 8415A/T 1/190 (.5) Present study
R/C2765 EX23 8504C/T CrT at CpG BsiHKAI 5/410 (1.2) Present study
V/M2782 EX23 8556G/A CrT at CpG NlaIII 1/210 (.5) Present study
G/R2814 EX23 8651G/A CrT at CpG, matches HG1 and 2 MspAlI 4/422 (.9) Present study
R/G2888 EX23 8873C/G At CpG/de novo change DsaI 1/190 (.5) Present study
V/I2905 EX23 8924G/A CrT at CpG XmnI 2/296 (.7) Present study
E/D2966 EX24 9109G/C 1/190 (.5) Present study
F/L3066 EX25 9406GT/CC 20/190 (10.5) Peral et al. 1997
T/M3509 EX35 10737C/T CrT at CpG SfaNI 2/384 (.5) Peral et al. 1997
A/V3511 EX35 10743C/T CrT at CpG HhaI 14/300 (4.7) Peral et al. 1997
I/V4044 EX44 12341A/G MscI 18/88 (20.5) Rossetti et al. 1996
A/V4058 EX45 12384C/T AvaII 15/188 (8.0) Rossetti et al. 1996
S/F4189 EX46 12777C/T Rare Peral et al. 1997
No amino acid change:
487G/A EX2 A92 CrT at CpG 1/146 (.7) Present study
1234C/T EX5 A341 CrT at CpG 3/146 (2.1) Present study
1330T/C EX5 L373 17/146 (11.6) Present study
1420C/T EX6 H403 1/146 (.7) Present study
1921C/T EX7 H570 CrT at CpG/matches HG2 1/146 (.7) Present study
7138C/T EX16 A2309 CrT at CpG 4/190 (2.1) Present study
7147G/A EX16 A2312 CrT at CpG 1/190 (.5) Present study
8650C/T EX23 S2813 CrT at CpG MspAII 3/190 (1.6) Present study
8890C/G EX23 S2893 At CpG 1/190 (.5) Present study
9541T/C EX26 P3310 Matches HG1, 2, and 3 20/190 (10.5) Peral et al. 1997
9880G/A EX28 T3223 CrT at CpG 1/128 (.8) Peral et al. 1997
11521G/A EX40 A3371 CrT at CpG 1/90 (1.1) Present study
11584G/C EX40 S3791 At CpG 2/90 (2.2) Peral et al. 1996b
12484A/G EX45 A4091 HhaI 27/100 (2.7) Peral et al. 1996b
12838C/T EX46 P4209 Rare Peral et al. 1997
12973C/T EX46 P4254 CrT at CpG AciI 1/90 (1.1) Peral et al. 1996b
examples of sequencing, see table 4 and fig. 3). The most
5′ mutation detected was a 13-bp deletion located just
13 bp after the translational start, and segregation of
this change with the disease is illustrated in figure 4B.
A second putative mutation was also identified in the
first exon—a missense change, L13Q, located within the
region encoding the signal peptide. Although it has not
been possible to show whether this change segregates
with the disease, because of lack of family members, this
nonconservative change significantly affects the hydro-
phobicity of the signal peptide. The hydrophobicity
score falls from a normal maximum of 1.54–1.15, and
the signal peptide probability score drops from a normal
of 9.2–6.7 (below the normal threshold of 7.0), sug-
gesting that this mutation would significantly impair the
function of this region. Two putative missense mutations
disrupt the structure of the leucine-rich repeat (LRR) or
flanking region. In pedigree 159, serine 75, in the first
LRR, is replaced by phenylalanine. This residue is con-
served from humans to Fugu in polycystin-1 and in many
other LRRs (Kobe and Deisenhofer 1994). The bulky
hydrophobic phenylalanine may disrupt the b-sheet
structure of this part of the motif. The second mutation
(in P267) replaces tryptophan 139 with a cysteine res-
idue in the LRR C-flanking region (Hughes et al. 1995).
The introduction of an additional cysteine may be dis-
ruptive by formation of inappropriate disulfide bonds in
an area that contains four highly conserved cysteines.
Direct sequencing of 2,062 bp of cDNA from exons
22–26 and 572 bp from exons 15–17 revealed an in-
frame deletion (6868del15), an insertion (8507ins12),
and a splicing event (IVS212delAG). In addition, six
nonconservative missense changes were detected in eight
different pedigrees (e.g., see fig. 3). Interestingly, in one
case, two segregating changes were detected within 90
amino acids (see table 4, pedigree P442), and one pu-
tative missense mutation, E2771K, was found in four
unrelated pedigrees. These missense changes were de-
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Figure 3 Examples of direct sequence analysis of patient DNA. A, The missense substitution E2771K, caused by GrA transition at
position 8522 nt. B, Two nonsense mutations S225X and Q227X, caused by CrA and CrT substitutions at positions 885 and 890 nt, respectively.
C, Normal and patient DNA with the mutation F1992L, 1993delT, caused by a single codon deletion, 6187del3. Note the double peak at the
site of a substitution (A and B) and continued double peaks after the deletion (C).
tected in the region homologous to the suREJ protein
and a related human protein, PKDREJ (Moy et al. 1996;
Hughes et al. 1999). The function and structure of this
area are unknown, so the consequences of the substi-
tutions are difficult to predict. Each of the substitutions
is at a position that is identical or highly conserved
in human, murine, and Fugu polycystin-1; four of the
six are also conserved in suREJ or PKDREJ. All of the
changes are nonconservative (see table 4), except
V2768M, where an additional change, G2858S, was de-
tected in the patient. Despite the segregation data and
the fact that no other changes were detected in these
patients, it will require further population analysis, a
better understanding of REJ structure, and, ultimately,
functional studies to determine whether these are path-
ogenic mutations.
One additional 3-bp deletion, resulting in a substi-
tution and single amino acid loss (F1992L and
1993delT), was found fortuitously during sequencing to
confirm another mutation in exon 15. In addition to
the missense mutations, 20 polymorphisms were de-
tected by direct sequencing of cDNA, genomic DNA,
and when confirming other mutations (table 5). Ten of
these changes resulted in an amino acid substitution,
and, although several of these were nonconservative, we
were able to demonstrate by segregation analysis or from
the screen of normal individuals that they were not path-
ogenic changes.
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Figure 4 Segregation of PKD1 mutations in pedigrees. A,
IVS71GrA segregates in pedigree 1 (P1). Restriction digest of PKD1
specifically amplified DNA (GenSeq 7) digested with MnI1. A 234-bp
fragment (arrow) is found in the affected individuals because of loss
of a restriction site. Samples numbered in the pedigree are in the cor-
responding gel lane. B, Genomic heteroduplex analysis of the mutation
224del13 in pedigree 103 (P103). Heteroduplexes (arrow) and two
homoduplex fragments, normal and deleted, can be seen in the affected
individuals.
Screening by Restriction Enzyme or Allele-Specific PCR
Prior to screening patients with PTT, samples were
analyzed with restriction enzymes and allele-specific
PCR (Peral et al. 1997) for known changes within the
single-copy region. In three pedigrees, mutations were
detected in this way: in P105, Q3513X; in P264,
R4020X; and in P252, R4227X (for details, see table
3). One further in-frame deletion (9245del18) was de-
tected by agarose gel electrophoresis during a screen to
determine the frequency of another polymorphism.
Discussion
We have described the first mutation screen of the entire
PKD1 gene, overcoming the problem of duplication at
this locus by anchored and PKD1-specific PCR and
screening for mutations by PTT and direct sequencing.
These data allow an objective analysis of the type and
position of pathogenic mutations, and the implications
for genetic diagnosis and understanding of the muta-
tional mechanism can be considered.
The first conclusion is that mutations are found
throughout the gene, from 13 bp 3′ to the initiating
codon to 228 bp 5′ to the stop codon (fig. 1). No clear
hotspot for mutation was found, with 69 different
changes characterized in 81 pedigrees. One missense
mutation, E2771K, was found in four pedigrees and
the stop mutation R4227X in three, whereas seven other
changes were identified in two families (table 4). Hap-
lotype analysis with PKD1 markers (see Subjects and
Methods section) showed in three cases (C2229X,
Q2243X, and Q3513X) that the mutation was on the
same or a nearly identical haplotype, indicating a prob-
able common origin, whereas the other six appeared to
be recurrent changes. Analysis of independent truncat-
ing events showed no significant frequency difference
between the single-copy region and the duplicated seg-
ment (14 in 20.2%, compared with 38 in 79.8% of the
translated region, respectively). However, the frequency
of changes in the 5′ half of the gene (212–6665 nt) was
significantly lower than that of the 3′ half (16–36;
, ). The area of the gene with the2x p 7.69 Pp .006
highest density of changes was 1 kb (7.7% of coding
DNA) 3′ to the halfway point (exons 15–18), accounting
for 26.9% of independent truncating events. It does not
appear that the uneven spread of mutations was due to
the methods used for screening, since lower levels were
detected in the 5′ region by PTT and sequencing. These
data suggest regions that may be screened initially for
mutations, but the functional significance, if any, will
require detailed analysis of the phenotypes in the dif-
ferent mutation groups.
The full range of disease associated mutations can be
evaluated in the 28.6% of the coding region that was
sequenced from genomic DNA (exons 1–8) or cDNA
(exons 15–17 and 22–26). In these areas, 17 missense
and in-frame mutations were identified in 19 pedigrees,
compared with 13 frame-shifting changes in 16 inde-
pendent pedigrees. Despite the evidence from segrega-
tion analysis, the screen of normal individuals, the lack
of other changes in the rest of the gene, and the non-
conservative nature of the substitutions (see the Results
section), it is likely that some of these missense changes
will ultimately be revealed as nonpathogenic polymor-
phisms. Nevertheless, it appears that as many as half
of all mutations will be missense or in-frame; therefore,
it seems reasonable to suspect that many of the undis-
covered mutations in this ADPKD population are mis-
sense changes to PKD1.
Studies of other genes have indicated that mRNAs
with nonsense or frameshifting mutations are often rap-
idly degraded by the RNA surveillance mechanism, non-
sense-mediated mRNA decay (Culbertson 1999; Hentze
and Kulozik 1999). However, in PKD1 we have de-
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tected most of this type of mutation by analysis of lym-
phoblast or leukocyte RNA, with equal peak intensity
seen by PTT (fig. 2) and sequencing, indicating that such
PKD1 mutant RNAs are not rapidly degraded. Fur-
thermore, the DNA screened region (exons 1–8) did not
reveal a higher level of truncating mutations. It is not
clear whether these mutated mRNA are stable because
functional alternatively spliced or cleaved products are
generated from these transcripts or whether they may
generate stable mutant proteins (Hughes et al. 1995;
International Polycystic Kidney Disease Consortium
1995; Ponting et al. 1999).
The results of the mutation screen, showing changes
throughout the gene, including a frameshifting mutation
within the signal-peptide-encoded region, are consistent
with the theory that PKD1 mutations are inactivating
and that disease occurs through a loss, or dosage re-
duction, of polycystin-1 protein. Nevertheless, the un-
even distribution of mutations along the gene, the sig-
nificant level of in-frame and missense events, and the
stability of mutant mRNAs indicates that this will be
an interesting population to analyze phenotype/geno-
type correlations.
By analyzing the pedigrees with PKD1 mutations, we
can estimate the frequency of new mutations at this
locus. Of a total of 411 affected individuals in 81 ped-
igrees, de novo mutation has been demonstrated in 7
cases by molecular analysis and has been suspected in
a further 8 because of documented negative imaging
studies or clinical indications in the parents. Overall,
this indicates a new mutation in 1 of 27.4 cases, and if
we assume a PKD1 population frequency of .001, the
new mutation rate is per gamete, per gen-51.8 # 10
eration. This estimated figure is higher than the average
for X-chromosomal disease genes (Stevenson and Kerr
1967) and the rate recently calculated for hemophilia
B (Green et al. 1999). It is, however, lower than previous
estimates for ADPKD, (Dobin et al. 1993)56.9 # 10
and (Dalgaard 1957), and is in line with56.5 # 10
other dominant disorders, especially those associated
with large genes (Vogel and Motulsky 1997).
This significant level of new mutation suggests a
steady increase in the disease frequency unless it is bal-
anced by a reduction in fitness. The many different
PKD1 mutations we have detected, mainly in a single
geographically defined PKD1 population (from a total
Oxford Renal Unit catchment of ∼0.6 M), and the lack
of common ancestral changes indicates that most mu-
tations have arisen in the last few generations, with
significant selection applied to eliminate these changes.
Early death (or renal death) before or during repro-
ductive age can occur, due to subarachnoid hemorrhage
or severe renal cystic disease, for instance. A second
means by which PKD1 mutations could be selected
against is if individuals (especially women) have a lower
reproductive fitness. Interestingly, data from Dalgaard
(1957) indicated a significantly lower level of repro-
duction for women with ADPKD, compared with the
age-matched Danish population (60%–80% expected).
It seems possible that a combination of reduced survival
and reduced reproductive fitness explains the observed
selection against PKD1 mutant alleles.
There have been suggestions that special factors pro-
mote mutation at PKD1 that may explain the relatively
high mutation rate (see Introduction section). The fre-
quency of mutations in the sequenced exons flanking
the polypyrimidine tract in IVS21 was analyzed. Exons
22–26 revealed putative mutations in 14 pedigrees, a
change every 80 bp, compared with an independent
change every 58 bp in exons 15–17 and one every 215
bp in the exon 1–8 region. In addition to disease-related
mutations, a number of polymorphisms were detected
in these fragments (table 5). If these substitutions are
also included, the frequency is 1/49 bp, exons 22–26;
1/48 bp, exons 15–17, and 1/132 bp, exons 1–8. Hence,
the frequency is higher both 3′ to and further 5′ of IVS21
than at the 5′ end of the gene. It is possible that the
polypyrimidine tract is having a long-range effect, re-
flecting the higher rate of mutation overall in the 3′ part
of the gene. However, a high level of multiple changes,
as found in experimental systems analyzing triplex
structures (Wang et al. 1996) was not found, and most
mutations were at sequences known to promote mu-
tation in other genes (see below).
The second suggested unusual mutational mechanism
at PKD1, conversion events with the HG loci, was
tested by seeing how many mutations match HG se-
quence. Analysis shows that 3/69 disease associated mu-
tations (4/81 pedigrees) and 3/22 polymorphisms match
the sequence of at least one HG sequence (for details,
see tables 4 and 5). So, although theHG-related changes
do not represent a large proportion of the total, this
level seems slightly higher than expected by chance, with
substitution levels of only ∼2%–3% found between the
HG and PKD1 gene (Loftus et al. 1999). However, four
of the changes are at CpG dinucleotides and one flanked
by tandem repeats, known sites of enhanced mutation
(see below), reflecting that they are sites of divergence
between PKD1 and the HG. Moreover, in five cases we
have analyzed the sequence flanking the PKD1 change
for other substitutions found in HG sequence, and, out
of 45 readable sites, no further HG-matching changes
were detected. These results indicate that these DNA
changes are not due to conversion with a significant
stretch of HG sequence, but the most likely explanation
is that they are recurrent events at sites with higher-
than-average rates of mutation. Because all HG loci
have not been sequenced, it is possible that other mu-
tations will match uncharacterized HG sequence. How-
ever, our mapping data indicate that the structure of the
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uncharacterized loci are similar to HG1 or HG2 and
so are unlikely to have many novel substitutions (au-
thors’ unpublished data). It is possible that the methods
we have employed, especially PKD1-specific PCR, may
not amplify PKD1 loci with mutations caused by larger
conversion events. However, higher rates of HG-match-
ing changes were not found in areas examined by an-
chored PCR, and the level of detected changes, consid-
ering that many areas have not been screened for
missense changes, does not leave a large reservoir of
undetected mutations that might be due to conversion
events.
If the positions and precise sites of PKD1 mutations
are examined, the mechanisms underlying the changes
mainly appear to be ones known to promote mutations
in other genomic regions. Of the 39 different substi-
tutions associated with mutation, 13 are at CpG din-
ucleotides, including 8 CrT transversions, that account
for all the recurrent substitutions, making a total of 20
of 46 independent substitutions at CpGs. These sites are
hotspots for mutation, because the cytosine is often
methylated and susceptible to spontaneous deamination
to give a thymidine, with a mutation rate ∼8.5 times
greater than average (Cooper et al. 1995). Conse-
quently, CpGs are significantly underrepresented in ver-
tebrate DNA (20% expected)—although CpG dinu-
cleotides constitute 7.2% of the PKD1 coding region
(higher than the genomic average of 0.8% because of
the GC richness of this area), they account for 43.5%
of the substitutions, an enrichment of sixfold. In an
analysis of the 31 deletions and insertions, 20 (including
the three recurrent events) are flanked by short stretches
of tandem-repeated sequence (for details, see table 4),
suggesting that slippage events during DNA replication
are the major cause of this type of change. Slippage
between tandem repeats is a well-characterized cause of
DNA deletions and duplications (Cooper et al. 1995).
We have shown that PKD1 has a relatively high mu-
tation rate but also that there is no clear evidence for
an unusual mechanism that can account for this. How-
ever, if we consider that a large number of different
mutations cause PKD1, possibly any inactivating mu-
tation, and that the PKD1 transcript is a large muta-
tional target (12,906-bp coding region), these factors
may in themselves explain the observed rate. If we con-
servatively estimate that 1,000 different mutations will
cause the disease, we can calculate a mutation rate, per
nucleotide, per generation, of , similar to that81.8 # 10
recently calculated from the factor IX gene (Giannelli
et al. 1999). In addition, PKD1 is unusually CpG-rich
(see above) and thus contains more highly mutable se-
quences. Hence, overall, it is not clear that germline
mutation at the nucleotide level in PKD1 is occurring
at a higher level than expected, and, probably, no special
mechanisms are required to explain the relatively high
gene-mutation rate. It remains to be seen whether un-
usual mechanisms are required to explain somatic mu-
tation at this locus.
In this study we have primarily used two methods for
mutation detection: PTT and direct sequencing. For
PTT, cDNA from cell lines or patient leukocytes is re-
quired to maintain an open reading frame, relatively
large fragments can be screened (∼2 kb of cDNA), and
almost all detected changes are pathogenic mutations.
This method could be improved if larger cDNA frag-
ments were amplified, as has been described for PKD1
(Thongnoppakhun et al. 1999). The major disadvantage
is that missense or small in-frame changes are not de-
tected, which are a significant source of mutation at
PKD1. Direct sequencing should detect every base-pair
mutation and any polymorphism in the sequence. Re-
cently, direct sequencing has been used to analyze the
COL4A5 gene in Alport syndrome (Martin et al. 1998)
and recommended as a primary mutation-screening
tool. To be effective however, the sequence quality has
to be very good, with heterozygotes detected as doublet
peaks and a low level of background, which is aided
by the Big Dye primer-labeling method. Also, it is rel-
atively expensive, since many small fragments have to
be sequenced for a large gene such as PKD1. For cost-
effective large-scale screening of PKD1 in the future, it
may be beneficial to introduce a rapid, inexpensive, and
semiautomated screening step, such as denaturing high-
performance liquid chromatography (Liu et al. 1998),
to flag fragments with base-pair changes for sequence
analysis.
The level of detection of PKD1 mutations in the
ADPKD pedigrees was 52.3%, and it was 61.7% in
known PKD1 pedigrees, indicating that some families
with PKD2 or unlinked ADPKD were represented in the
population. These figures compare well with primary
screens of other large disease genes, such as COL4A5
in Alport syndrome (Knebelmann et al. 1996) and the
fibrillin-1 gene in Marfan syndrome (Hayward et al.
1997). Furthermore, nearly 75% of the gene was not
screened for missense and in-frame changes. These re-
sults show the feasibility of molecular diagnosis of
PKD1. Although the demand for presymptomatic
screening is, at present, low, if and when therapies are
developed to treat this disorder, it will be essential that
diagnosis is possible in younger individuals, for whom
imaging methods are less reliable, so that treatment can
start at an early age, before significant renal damage
has occurred.
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